SND Bio

SND Bio is a clinical-stage biotechnology company focused on developing next-generation antibody therapeutics for oncology. The company leverages its proprietary Selective Native-like Dual-targeting (SND) platform to create biologics that offer enhanced precision and reduced off-target toxicity compared to existing immunotherapies. Its lead candidate, SND-001, is a novel CD38-targeted antibody designed to treat multiple myeloma by selectively binding to tumor cells while minimizing impact on healthy blood cells. SND Bio is headquartered in South San Francisco and is led by a team with extensive experience in antibody engineering and drug development. The company's approach aims to overcome the limitations of current treatments by improving the therapeutic index of established targets.